Investigating the effects of remote ischemic preconditioning on blood characteristics in healthy adults
Effects of Remote Ischemic Preconditioning on Peripheral Blood Biomarkers in Healthy Adults (EMINENT): a Single-centre, Open-label, Randomized Controlled Clinical Trial
This study is testing how a special technique called remote ischemic preconditioning affects the blood of healthy adults to see if it can help protect their hearts.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT05957523 on ClinicalTrials.gov |
What this trial studies
This study aims to explore how remote ischemic preconditioning (RIPC) affects the peripheral blood characteristics of healthy adults. It will recruit 60 volunteers who will be randomly assigned to either a high-frequency or low-frequency RIPC group. The high-frequency group will undergo RIPC twice daily for seven days, while the low-frequency group will participate once daily. Blood samples will be collected before, during, and after the training to analyze changes in blood components and understand the mechanisms behind RIPC's protective effects on the cardiovascular system.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 18 to 45 years who meet the inclusion criteria.
Not a fit: Patients with cardiovascular, endocrine, hematologic, infectious, neurological, or vascular diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into new methods for protecting the cardiovascular system from ischemia/reperfusion injury.
How similar studies have performed: While the concept of remote ischemic preconditioning has been explored, this specific approach and its effects on healthy adults is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 to 45 years; * Be in good health; * Consent to participate in the clinical trial and sign the informed consent form. Exclusion Criteria: * Abnormal results in biochemical checks and physiological indicators. * Cardiovascular and cerebrovascular diseases: hypertension, coronary heart disease, congenital heart disease, cerebrovascular alterations, etc. * Endocrine diseases: diabetes, thyroid disorders, etc. * Hematologic diseases: anemia, paroxysmal hemoglobinuria, primary thrombocytosis, etc. * Infectious diseases: hepatitis B, hepatitis C, syphilis, etc. * Cancer. * Neurological and psychiatric disorders. * Vascular diseases: peripheral vascular disease, Raynaud's syndrome, thromboembolic diseases. * Major trauma or surgery within the last six months. * Pregnant or breastfeeding women. * Upper limbs unsuitable for compression treatment: history of upper limb surgery, presence of tissue damage and limb deformity, and concomitant hemorrhagic diseases. * Recent circumstances that may affect results: blood donors within the last month, any medication taken within the last month, fever within the last week, women within their menstrual cycle or within 7 days before the start of menstruation. * Patients who refuse to sign the informed consent form for participation in this study.
Where this trial is running
Xi'an, Shaanxi
- First Affiliated Hospital of Xian Jiantong University — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Principal investigator: Guoliang Li — First Affiliated Hospital Xi'an Jiaotong University
- Study coordinator: Guoliang Li
- Email: liguoliang_med@163.com
- Phone: 00-86-029-85323805
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.